WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

In vitro ADME services

A unique opportunity to measure drug ADME in vitro without using animals


Our in vitro assays are highly predictive of clinical results. Studies investigating drug metabolism, metabolite identification, permeability, and bioavailability are conducted using human highly functional, metabolically competent single- and multi-organ models.

Service overview:

We offer a range of single- and multi-organ models to derive human-relevant data to better inform the selection of lead candidates with desirable ADME properties.

Through this service, you can utilize a combination of our expertise and highly metabolically active, long-term cultures to derive unique in vitro data.

  • Hepatic clearance including low clearance compounds and metabolite identification, including Phase I and II metabolites
  • Gut metabolism and permeability
  • Lung permeability in upper and lower airway models
  • Bioavailability prediction using multi-organ models to simulate route of administration
  • Method developed with protein-free cell culture medium in conjunction with low non-specific binding multi-chip assay plates

Customer feedback

Working with CN Bio has been a pleasure, the team listened to our non-trivial requirements and made useful suggestions to help meet objectives. During the course of the project, the team were responsive and helpful. The results were delivered as agreed and helped us to move towards our goals.

Dr Giuseppe Ferrandino

Senior Translational Scientist at Owlstone Medical

View more PhysioMimix reviews on SelectScience

Dr Giuseppe Ferrandino

How the service works:

Utilizing our PhysioMimix OOC systems allows the modeling of human ADME profiles in liver, gut, lung, or multi-organ combinations.

This in vitro service generates novel insights into the human body’s effect on drugs, previously only possible using animal models.

Your dedicated contact will work collaboratively with you from the start to the end of the project.

  1. Design and finalize experiment plan 
  2. Customer supplies required amount of drug(s)
  3. Growth and preparation of organ models prior to treatment – between four and 21 days, dependent on assay selected
  4. Compound dosing and sample collection over one to four days
  5. One to two weeks to run endpoint assays, analyze data, and complete the report 
  6. ~ two months to complete the study from receiving order 
  7. Media samples sent to customer, or third party for LC-MS analysis

Standard liver drug metabolism cell culture timeline

Timeline of a standard liver drug metabolism cell culture

Endpoint measurements

milti chip plates |

Included, but are not limited to:

Functionality biomarkers

Liver
  • Cytochrome P450 enzyme activity
  • Albumin production
  • Urea production
  • Lactose dehydrogenase  (LDH) release
Gut, or Lung
  • Trans epithelial electrical resistance (TEER)
  • Lactose dehydrogenase  (LDH) release

Profiling analysis

Liver
  • Media samples ready for LC/MS analysis
  • Quantitative PCR assessment of Cytochrome P450 enzyme functionality
Gut, or Lung
  • Media samples ready for LC/MS analysis

Related applications

drug absorption app |

Drug absorption

Our co-culture gut and lung absorption assays provide in vivo-like biological barrier properties to study compound absorption rates and more closely predict human outcomes.

Learn more
drug met app |

Drug metabolism

Our liver, lung, and gut in vitro models can be used separately or in combination to study drug metabolism. These stable, human models accurately mimic the complexity of the physiological environment and offer a major advance for studying DMPK.

Learn more
drug bio app |

Drug bioavailability

Our multi-organ oral bioavailability assay with connected gut and liver models can provide accurate predictions of human bioavailability early in drug development, improving the chance of success in clinical trials.

Learn more
T12 plate close up

Learn more about our ADME Services

Request more info

Featured resource

Scientific publications

Characterizing Repreducibility MPS 2020 Graphic |

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation

Posters

Gut Liver OOC Combined with In Silico Modelling |

Gut-liver organ-on-a-chip combined with in silico modeling as a promising tool for investigation of mycophenolate mofetil pharmocokinetics

Scientific publications

Exploration Application Drug Metabolism 2022 Graphic |

Exploration and Application of a Liver-on-a-Chip Device in Combination with Modelling and Simulation for Quantitative Drug Metabolism Studies

View all ADME related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023